ValuEngine cut shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a sell rating in a report released on Wednesday morning.
A number of other equities research analysts have also weighed in on TBPH. Cantor Fitzgerald reiterated a buy rating and issued a $55.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, November 7th. Needham & Company LLC reiterated a buy rating on shares of Theravance Biopharma in a research report on Tuesday, December 5th. BidaskClub upgraded Theravance Biopharma from a strong sell rating to a sell rating in a research report on Saturday, January 20th. Finally, Leerink Swann lifted their price target on Theravance Biopharma from $45.00 to $48.00 and gave the company an outperform rating in a research report on Thursday, February 8th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $42.00.
Shares of Theravance Biopharma (NASDAQ TBPH) traded up $0.07 during mid-day trading on Wednesday, hitting $28.61. The stock had a trading volume of 267,695 shares, compared to its average volume of 220,718. Theravance Biopharma has a 12-month low of $22.90 and a 12-month high of $43.44. The company has a debt-to-equity ratio of 1.94, a quick ratio of 5.79 and a current ratio of 6.05.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.